RxDoctor Payments Data

Helmut Rauch, MD

Family Medicine · Harker Heights, TXNPI 1831504141

Payments from drug & device makers

$506in general payments, 2019–2025

Across 27 payments — averaging $18.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$151
  • Pfizer$70
  • GSK$53
  • Abbott$49
  • AbbVie$48
  • Boehringer Ingelheim$35
  • plus $99 from 5 others

What the payments were for

  • Food & beverage$47193%
  • Education$357%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk10$151
Pfizer3$70
GSK3$53
Abbott2$49
AbbVie(2 entities)2$48
Boehringer Ingelheim1$35
Merck2$27
Medtronic1$20
Lilly USA, LLC1$20
Nevro Corp.1$19
Circassia Inc.1$13

How this compares

$506 in reported general payments places this provider in the 50th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$144,559
Medicare patients
508
Services billed
1,918

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide109$152,810
JardianceEmpagliflozin68$97,159
TrulicityDulaglutide35$60,470
JanuviaSitagliptin Phosphate29$37,507
EliquisApixaban25$30,632
Tresiba Flextouch U-100Insulin Degludec27$28,980
XareltoRivaroxaban31$26,328
FarxigaDapagliflozin Propanediol19$25,879
RybelsusSemaglutide11$25,526
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$24,291
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$21,757
MyrbetriqMirabegron23$19,360
LinzessLinaclotide15$18,766
TradjentaLinagliptin11$17,362
Breo ElliptaFluticasone/Vilanterol25$11,569

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$151$178,336120 claims
Boehringer IngelheimJardiance, Tradjenta, Jentadueto$35$124,21790 claims
Lilly USA, LLCTrulicity$20$60,47035 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$53$47,12675 claims
MerckJanuvia$27$37,50729 claims
PfizerEliquis$70$30,63225 claims
AbbVieLinzess$48$18,76615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Harker Heights

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →